Technical Analysis for TSBX - Turnstone Biologics Corp.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| F | 3.58 | -4.28% | -0.16 |
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | N/A | N/A | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| New 52 Week Closing Low | Bearish | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| New 52 Week Low | Weakness | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| New 52 Week Closing Low | Bearish | -4.28% | |
| New 52 Week Low | Weakness | -4.28% | |
| Wide Bands | Range Expansion | -4.28% | |
| Oversold Stochastic | Weakness | -4.28% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| Possible NR7 | 3 days ago |
| Possible Inside Day | 3 days ago |
| 60 Minute Opening Range Breakdown | 3 days ago |
| Up 5% | 3 days ago |
| 60 Minute Opening Range Breakout | 3 days ago |
Free Daily (Stock) Chart Reading
- Earnings date: 08/30/2023
Turnstone Biologics Corp. Description
Turnstone Biologics is a clinical-stage biotechnology company developing new medicines to treat and cure solid tumors by pioneering a differentiated approach to TIL therapy. Turnstone’s innovative TIL therapy is based upon the identification, selection, and expansion of the most potent tumor-reactive T cells, known as Selected TILs, and is designed to overcome the limitations of first-generation bulk TILs that have demonstrated objective responses only in limited tumor types. Turnstone’s most advanced program, TIDAL-01, is currently being evaluated in two Phase 1 studies in patients with melanoma, breast cancer, and colorectal cancer, and the Company is also actively advancing its preclinical pipeline programs including TIDAL-02, its next Selected TIL program, and its TIDAL-01 and viral immunotherapy combination program.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Cancer Solid Tumors Immunotherapy Breast Cancer Melanoma Colorectal Cancer Tumor Infiltrating Lymphocytes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 13.2 |
| 52 Week Low | 3.57 |
| Average Volume | 80,529 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 0.00 |
| 20-Day Moving Average | 7.57 |
| 10-Day Moving Average | 4.67 |
| Average True Range | 1.00 |
| RSI (14) | 21.88 |
| ADX | 31.18 |
| +DI | 10.15 |
| -DI | 33.35 |
| Chandelier Exit (Long, 3 ATRs) | 9.17 |
| Chandelier Exit (Short, 3 ATRs) | 6.56 |
| Upper Bollinger Bands | 13.75 |
| Lower Bollinger Band | 1.40 |
| Percent B (%b) | 0.18 |
| BandWidth | 162.96 |
| MACD Line | -1.96 |
| MACD Signal Line | -1.62 |
| MACD Histogram | -0.3397 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 4.12 | ||||
| Resistance 3 (R3) | 4.18 | 4.05 | 4.03 | ||
| Resistance 2 (R2) | 4.05 | 3.92 | 4.03 | 4.00 | |
| Resistance 1 (R1) | 3.82 | 3.83 | 3.76 | 3.76 | 3.97 |
| Pivot Point | 3.69 | 3.69 | 3.66 | 3.67 | 3.69 |
| Support 1 (S1) | 3.46 | 3.56 | 3.40 | 3.40 | 3.19 |
| Support 2 (S2) | 3.33 | 3.47 | 3.31 | 3.16 | |
| Support 3 (S3) | 3.10 | 3.33 | 3.13 | ||
| Support 4 (S4) | 3.04 |
